|
PDS Biotechnology Corporation (PDSB) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
PDS Biotechnology Corporation (PDSB) Bundle
تتيح لك حاسبة PDSB DCF المصممة للدقة ، تقييم تقييم شركة التكنولوجيا الحيوية PDS باستخدام البيانات المالية في العالم الحقيقي ، مما يوفر مرونة كاملة لتعديل جميع المعلمات الرئيسية للتوقعات المحسنة.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -7.2 | -14.7 | -21.2 | -41.6 | -40.1 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .1 | .2 | .2 | .0 | .1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -7.3 | -14.8 | -21.4 | -41.7 | -40.1 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 12.2 | 28.8 | 65.2 | 73.8 | 56.6 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.2 | 1.4 | 1.3 | 1.2 | 7.0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 3.17 | 3.17 | 3.17 | 3.17 | 3.17 | 3.17 | 3.17 | 3.17 | 3.17 | 3.17 |
| EBITAT | -7.0 | -14.8 | -16.9 | -40.5 | -38.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -5.7 | -14.5 | -16.8 | -40.5 | -33.0 | -7.0 | .0 | .0 | .0 | .0 |
| WACC, % | 14.3 | 14.64 | 13.28 | 14.45 | 14.43 | 14.22 | 14.22 | 14.22 | 14.22 | 14.22 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -6.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -6 | |||||||||
| Net Debt | -33 | |||||||||
| Equity Value | 27 | |||||||||
| Diluted Shares Outstanding, MM | 31 | |||||||||
| Equity Value Per Share | 0.86 |
What You Will Get
- Real PDSB Financial Data: Pre-filled with PDS Biotechnology Corporation’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See PDSB’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for PDS Biotechnology Corporation (PDSB).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs for accurate assessments.
- Customizable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for PDS Biotechnology Corporation (PDSB).
- Interactive Dashboard and Charts: Visual representations present key valuation metrics for straightforward analysis.
How It Works
- Download: Obtain the pre-formatted Excel file containing PDS Biotechnology Corporation's (PDSB) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time as you make changes.
- Test Scenarios: Develop various projections and instantly compare the results.
- Make Decisions: Leverage the valuation findings to inform your investment choices.
Why Choose This Calculator for PDS Biotechnology Corporation (PDSB)?
- Accurate Data: Up-to-date financial information for PDSB ensures trustworthy valuation outcomes.
- Customizable: Tailor essential metrics like growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted specifically for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Easy-to-navigate design and comprehensive instructions cater to users of all experience levels.
Who Should Use This Product?
- Investors: Accurately assess PDS Biotechnology Corporation’s (PDSB) fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to PDSB.
- Consultants: Easily customize the template for valuation reports tailored to PDSB clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to the biotech sector.
What the Template Contains
- Preloaded PDSB Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.